Wednesday, July 8, 2026
🇺🇸 FDA

Patent directory · USPTO A61K / A61P

Patents matching “Agios Pharmaceuticals, Inc.”

93 pharma patents match "Agios Pharmaceuticals, Inc." in our USPTO index (A61K/A61P) — applicant, grant date, expiration, and drug links.

Matches 93
Index total 30,257
Page 4 / 4

Quick answer

This filtered view shows 93 pharmaceutical patents matching "Agios Pharmaceuticals, Inc." in our USPTO PatentsView index (CPC A61K/A61P). Search matches patent number, title, applicant, and CPC classification codes.

Patent results

93 results for “Agios Pharmaceuticals, Inc.” · 30,257 patents in full index Clear search

  1. US 9579324

    Therapeutically active compounds and their methods of use

    Agios Pharmaceuticals, Inc. · Granted Feb 28, 2017 · Expires Feb 23, 2037

    granted

  2. US 9512107

    Therapeutically active compositions and their methods of use

    Agios Pharmaceuticals, Inc. · Granted Dec 6, 2016 · Expires Dec 1, 2036

    granted

  3. US 9474779

    Therapeutically active compositions and their methods of use

    Agios Pharmaceuticals, Inc. · Granted Oct 25, 2016 · Expires Oct 20, 2036

    granted

  4. US 9458132

    Therapeutic compounds and compositions and their use as PKM2 modulators

    Agios Pharmaceuticals, Inc. · Granted Oct 4, 2016 · Expires Sep 29, 2036

    granted

  5. US 9403792

    Methods of using pyruvate kinase activators

    Agios Pharmaceuticals, Inc. · Granted Aug 2, 2016 · Expires Jul 28, 2036

    granted

  6. US 9404081

    Pyruvate kinase activators for use in therapy

    Agios Pharmaceuticals, Inc. · Granted Aug 2, 2016 · Expires Jul 28, 2036

    granted

  7. US 9388164

    Methods of using pyruvate kinase activators

    Agios Pharmaceuticals, Inc. · Granted Jul 12, 2016 · Expires Jul 7, 2036

    granted

  8. US 9365545

    Therapeutic compounds and compositions

    Agios Pharmaceuticals, Inc. · Granted Jun 14, 2016 · Expires Jun 9, 2036

    granted

  9. US 9328077

    Bicyclic PKM2 activators

    Agios Pharmaceuticals, Inc. · Granted May 3, 2016 · Expires Apr 28, 2036

    granted

  10. US 9303002

    Compounds and their methods of use

    Agios Pharmaceuticals, Inc. · Granted Apr 5, 2016 · Expires Mar 31, 2036

    granted

  11. US 9221792

    N-(4-(azetidine-1-carbonyl) phenyl)-(hetero-) arylsulfonamide derivatives as pyruvate kinase M2 (PMK2) modulators

    Agios Pharmaceuticals, Inc. · Granted Dec 29, 2015 · Expires Dec 24, 2035

    granted

  12. US 9199968

    Therapeutic compounds and compositions

    Agios Pharmaceuticals, Inc. · Granted Dec 1, 2015 · Expires Nov 26, 2035

    granted

  13. US 9193701

    Pyruvate kinase activators for use in therapy

    Agios Pharmaceuticals, Inc. · Granted Nov 24, 2015 · Expires Nov 19, 2035

    granted

  14. US 9181231

    Pyruvate kinase activators for use for increasing lifetime of the red blood cells and treating anemia

    Agios Pharmaceuticals, Inc. · Granted Nov 10, 2015 · Expires Nov 5, 2035

    granted

  15. US 9115086

    Therapeutic compositions and related methods of use

    Agios Pharmaceuticals, Inc. · Granted Aug 25, 2015 · Expires Aug 20, 2035

    granted

  16. US 9108921

    Therapeutic compounds and compositions

    Agios Pharmaceuticals, Inc. · Granted Aug 18, 2015 · Expires Aug 13, 2035

    granted

  17. US 8889667

    Therapeutic compounds and compositions

    Agios Pharmaceuticals, Inc. · Granted Nov 18, 2014 · Expires Nov 13, 2034

    granted

  18. US 8883438

    Method for diagnosing cell proliferation disorders having a neoactive mutation at residue 97 of isocitrate dehydrogenase 1

    Agios Pharmaceuticals, Inc. · Granted Nov 11, 2014 · Expires Nov 6, 2034

    granted

  19. US 8785450

    Therapeutic compounds and compositions

    Agios Pharmaceuticals, Inc. · Granted Jul 22, 2014 · Expires Jul 17, 2034

    granted

  20. US 8742119

    Pyruvate kinase M2 modulators, therapeutic compositions and related methods of use

    Agios Pharmaceuticals, Inc. · Granted Jun 3, 2014 · Expires May 29, 2034

    granted

  21. US 8501953

    PKM2 modulators for use in the treatment of cancer

    Agios Pharmaceuticals, Inc. · Granted Aug 6, 2013 · Expires Aug 1, 2033

    granted

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.